Argus Research analyst David Toung maintains $Quest Diagnostics (DGX.US)$ with a buy rating, and adjusts the target price from $165 to $175.
According to TipRanks data, the analyst has a success rate of 63.8% and a total average return of 9.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The firm's outlook on Quest Diagnostics has been positively influenced by the integration of LifeLabs, which is a key factor behind the revised guidance, as well as persisting high utilization trends. The firm holds a favorable view on Quest, highlighting its defensive qualities amid an election cycle and more secure estimates for the coming years.
Quest Diagnostics delivered a strong performance in their third-quarter results, surpassing expectations. The company also maintained its earnings forecast despite challenges posed by hurricanes, and provided an encouraging preliminary outlook for fiscal 2025.
The firm has increased its estimates following Quest Diagnostics' strong third-quarter outcomes and encouraging preliminary outlook for 2025. The company's earnings visibility is deemed to remain robust due to consistent underlying healthcare utilization trends, gains in market share, and a favorable mix.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
阿格斯分析师David Toung维持$奎斯特诊疗 (DGX.US)$买入评级，并将目标价从165美元上调至175美元。
根据TipRanks数据显示，该分析师近一年总胜率为63.8%，总平均回报率为9.7%。
此外，综合报道，$奎斯特诊疗 (DGX.US)$近期主要分析师观点如下：
公司对奎斯特诊疗的前景受到了对北美最大医疗实验室LifeLabs的整合的积极影响，这是修订指引背后的关键因素，同时也受持续的高利用率趋势影响。公司对奎斯特持有积极看法，强调其在选举周期和未来几年更安全的估计背景下的防御品质。
奎斯特诊疗在第三季度业绩表现强劲，超出预期。尽管飓风带来挑战，公司仍然保持其盈利预测，并对2025财年提出了令人鼓舞的初步前景。
公司根据奎斯特诊疗业绩强劲的第三季度成果和令人鼓舞的2025财年初步前景提高了其估计。由于持续的基础医疗利用趋势、市场份额增加和有利的组合，公司的盈利可见度被认为将保持强劲。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
